Biofrontera’s (BFRI) Buy Rating Reaffirmed at Benchmark

Biofrontera (NASDAQ:BFRI)‘s stock had its “buy” rating reaffirmed by stock analysts at Benchmark in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $7.00 target price on the stock.

Biofrontera Price Performance

Biofrontera stock traded up $0.02 during mid-day trading on Friday, hitting $0.72. 117,628 shares of the company were exchanged, compared to its average volume of 1,007,359. Biofrontera has a 12-month low of $0.61 and a 12-month high of $4.04. The company has a market capitalization of $4.01 million, a P/E ratio of -0.30 and a beta of 0.50. The business’s 50 day simple moving average is $1.03 and its two-hundred day simple moving average is $1.10.

Biofrontera (NASDAQ:BFRI) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $0.07. Biofrontera had a negative net margin of 36.31% and a negative return on equity of 652.37%. The business had revenue of $7.84 million for the quarter, compared to the consensus estimate of $9.02 million. Equities research analysts predict that Biofrontera will post -3.11 earnings per share for the current year.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.